Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + spartalizumab in advanced oesogastric adenocarcinoma
2021-001401-67Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capmatinib and spartalizumab in Gastroesophageal junction adenocarcinoma (GEJA), gastroesophageal junction adenocarcinoma and gastric adenocarcinoma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall response rate. Started Apr 2021; status: terminated.
02
Drugs
capmatinibspartalizumab
03
Conditions
Gastroesophageal junction adenocarcinoma (GEJA)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on 2021-001401-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001401-67.